Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ovum Therapeutics

www.orumrx.com

Latest From Ovum Therapeutics

Venture Funding Deals: $688.8m In Financings From Avitide To Zai Lab

June venture capital financings for emerging companies totaled more than $688.8m, ranging from an undisclosed round for Avitide to a $120m Series B for Rubius Therapeutics.

Financing Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Ovum Therapeutics
  • Senior Management
  • Sung Joo Lee, PhD, CEO
  • Contact Info
  • Ovum Therapeutics
    N511, 11-3, Techno-1-Ro
    Yusung-Gu
    Daejeon, 34015
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register